JP2025515011A5 - - Google Patents

Info

Publication number
JP2025515011A5
JP2025515011A5 JP2024564553A JP2024564553A JP2025515011A5 JP 2025515011 A5 JP2025515011 A5 JP 2025515011A5 JP 2024564553 A JP2024564553 A JP 2024564553A JP 2024564553 A JP2024564553 A JP 2024564553A JP 2025515011 A5 JP2025515011 A5 JP 2025515011A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
aon1
agent according
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/066540 external-priority patent/WO2023215781A1/en
Publication of JP2025515011A publication Critical patent/JP2025515011A/ja
Publication of JP2025515011A5 publication Critical patent/JP2025515011A5/ja
Pending legal-status Critical Current

Links

JP2024564553A 2022-05-05 2023-05-03 デュシェンヌ型筋ジストロフィーを治療する方法 Pending JP2025515011A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263364260P 2022-05-05 2022-05-05
US63/364,260 2022-05-05
US202263387733P 2022-12-16 2022-12-16
US63/387,733 2022-12-16
PCT/US2023/066540 WO2023215781A1 (en) 2022-05-05 2023-05-03 Method of treating duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
JP2025515011A JP2025515011A (ja) 2025-05-13
JP2025515011A5 true JP2025515011A5 (enExample) 2026-05-14

Family

ID=86771292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564553A Pending JP2025515011A (ja) 2022-05-05 2023-05-03 デュシェンヌ型筋ジストロフィーを治療する方法

Country Status (12)

Country Link
US (1) US20230416741A1 (enExample)
EP (1) EP4519439A1 (enExample)
JP (1) JP2025515011A (enExample)
KR (1) KR20250006069A (enExample)
CN (1) CN119095962A (enExample)
AU (1) AU2023265665A1 (enExample)
CA (1) CA3257018A1 (enExample)
CL (2) CL2024003326A1 (enExample)
IL (1) IL316800A (enExample)
MX (1) MX2024013409A (enExample)
TW (1) TW202406557A (enExample)
WO (1) WO2023215781A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069511A1 (en) * 2020-09-30 2022-04-07 Biomarin Technologies B.V. Antisense oligonucleotides targeting the exon 51 of dystrophin gene

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
MA46427A (fr) * 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP2020536058A (ja) * 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
JP7345466B2 (ja) * 2018-06-26 2023-09-15 日本新薬株式会社 アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用
US12331293B2 (en) * 2018-11-02 2025-06-17 Biomarin Technologies B.V. Bispecific antisense oligonucleotides for dystrophin exon skipping
WO2022069511A1 (en) 2020-09-30 2022-04-07 Biomarin Technologies B.V. Antisense oligonucleotides targeting the exon 51 of dystrophin gene

Similar Documents

Publication Publication Date Title
JP2019536464A5 (enExample)
JP7000343B2 (ja) 一本鎖rnaを提供する方法
JP2023123756A5 (enExample)
JP2020536125A5 (enExample)
US20170073679A1 (en) Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
JP2022525428A5 (enExample)
TWI335352B (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US20030229040A1 (en) Cationic liposomal delivery system and therapeutic use thereof
JP2018529732A5 (enExample)
JP2024541962A5 (enExample)
JP2019532080A5 (enExample)
US6559129B1 (en) Cationic liposomal delivery system and therapeutic use thereof
UA77945C2 (en) Use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders (variants), pharmaceutical composition (variants)
JP2022525429A5 (enExample)
TW201408309A (zh) 用於治療b型肝炎及d型肝炎感染之方法
JP2019513384A5 (enExample)
JP2020537637A5 (enExample)
CA3172823A1 (en) Methods and compositions for targeting pd-l1
JP2024518947A5 (enExample)
EP3349730B1 (en) Systems for nucleic acid expression in vivo
JP2024540994A5 (enExample)
US20030215489A1 (en) Chemosensitizing with liposomes containing oligonucleotides
JP5674923B2 (ja) アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法
RU2014130022A (ru) Ингибиторы сиалоадгезина для лечения заболеваний, вызванных вирусами, имеющими оболочку
JP2019500334A5 (enExample)